Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020
BackgroundWhether the high cost of cancer drugs is commensurate with their value to patients, which has become the focus of public concern. We aimed to assess the value of new cancer drugs approved for solid cancer in China and to explore the association between price and value of drugs.MethodsWe id...
Saved in:
Main Authors: | Jing Luo (Author), Shunlong Ou (Author), Hua Wei (Author), Xiaoli Qin (Author), Rui Peng (Author), Song Wang (Author), Qian Jiang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NMPA-approved traditional Chinese medicine-Pingwei Pill: new indication for colistin recovery against MCR-positive bacteria infection
by: Qiushuang Sheng, et al.
Published: (2021) -
Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
by: Shun-Long Ou, et al.
Published: (2023) -
Added therapeutic value of new drugs approved in Brazil from 2004 to 2016
by: Rogério Hoefler, et al.
Published: (2019) -
Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001-2020Research in context
by: Yuxuan Wei, et al.
Published: (2024) -
Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories
by: Xiaoyi Chen, et al.
Published: (2024)